qbx258
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01479595)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-13INHIBITOR
IL13 inhibitor
- Interleukin-4INHIBITOR
IL4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- qbx258
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02494206 | N/A | Jul 1, 2015 | Cornell University, Novartis |
| NCT01479595 | Phase 2 | Feb 1, 2012 | Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 1 | 2 | 2012 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1